BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mehterov N, Kazakova M, Sbirkov Y, Vladimirov B, Belev N, Yaneva G, Todorova K, Hayrabedyan S, Sarafian V. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy. Genes (Basel) 2021;12:1085. [PMID: 34356101 DOI: 10.3390/genes12071085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wookey PJ, Gupta P, Hare DL, Ciccotosto GD, Hutchings CJ. Splice Variants of G Protein-Coupled Receptors Expressed in Cancers: Effective Targeting with Monoclonal Antibodies and Antibody-Like Scaffolds As Ligands Irrespective of the Pharmacological Status of Isoforms. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_261-1] [Reference Citation Analysis]
2 Marima R, Francies FZ, Hull R, Molefi T, Oyomno M, Khanyile R, Mbatha S, Mabongo M, Owen Bates D, Dlamini Z. MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets. Biomedicines 2021;9:1818. [PMID: 34944633 DOI: 10.3390/biomedicines9121818] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Reviejo M, Soto M, Lozano E, Asensio M, Martínez-Augustin O, Sánchez de Medina F, Marin JJG. Impact of alternative splicing on mechanisms of resistance to anticancer drugs. Biochem Pharmacol 2021;193:114810. [PMID: 34673012 DOI: 10.1016/j.bcp.2021.114810] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]